INSOMNIA AGENTS PRIOR AUTHORIZATION / MEDICAL NECESSITY DETERMINATION

PRESCRIBER FAX FORM

Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. Start saving time today by filling out this prior authorization form electronically. Visit www.NaviNet.net/hzdpa to register and then begin using this free service as part of your existing NaviNet account.

PATIENT AND INSURANCE INFORMATION				Today's Date:				
Patient Name (First): Last:						M:	DOB (mm/dd/yyyy):	
Patient Address: City, State, Z):			Patient Telephone:		
Member ID Number:			Group Number:					
PRESCRIBER/CLINIC IN	FORMATION							
Prescriber Name: Prescriber NPI#:		r NPI#:		Specialty:		Contact Name:		
Clinic Name:			Clinic Address:					
City, State, Zip:			Phone #:		Secure	Secure Fax #:		
PLEASE ATTACH ANY A	DDITIONAL INFORM	ATION THAT	SHOUL	D BE CONSIDER	ED WITH T	ГНІЅ	REQUEST	
Patient diagnosis (ICD co			311002	<u>D DE GONOIDEIX</u>			NEGOLO!	
Medication requested:			Strength:					
Dosing schedule:				Quanti	ty per mon	ıth:		
							Yes No	
(i.e., eszopiclone, za If no, is there a intolerance or h	MedWatch form (http:/ ypersensitivity to TWC	nin the past 90 o //fda.gov/media/) prerequisite ao	days? N /76299/ gents (i.	ledical records a download) showin e., eszopiclone, za	re required g the patien aleplon , zo	d. nt ha: olpide	Yes □ No s an	
	ere medical records s							
prerequisite 3. Are there medical re therapy with a non-c	e agents (i.e., eszopicle cords showing the req ontrolled agent (Silenc	one, zaleplon , : uested agent is or, doxepin, ram	zolpide a non- nelteon,	m)? Medical reco controlled agent A or Rozerem)?	rds are rqu ND the pat	u ired tient r	Yes No requires	
4. Does the requested	quantity (dose) exceed	d the maximum	FDA la	beled dose for the	requested	diag	nosis? Yes No nosis? Yes No ted diagnosis:	
not exceed the pr	uested quantity (dose) ogram quantity limit?. explain why the reque						at does Yes No	
Please fax or mail this f Horizon Blue Cross Blue c/o Prime Therapeutics L	Shield of New Jersey LC, Clinical Review D	epartment	for th	e use of the individing information that	dual entity t t is privilege	to wh ed or	mmunication is intended only ich it is addressed, and may confidential. If the reader of	

Ames Crossing Road Suite 200

Eagan, MN 55121

TOLL FREE

Fax: 877.897.8808 Phone: 888.214.1784 that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 888.214.1784, and return the original message to Horizon Blue Cross Blue Shield of New Jersey c/o Prime Therapeutics via U.S. Mail. Thank you for your cooperation.